OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002 · Astellas Pharma Global Development, Inc. · PHASE1/PHASE2 · terminated · last registry update 2026-01-05 · Acute myeloid leukemia · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“The study was terminated due to enrollment challenges.”Open Targets' class: insufficient enrollmentRegistry record, Astellas Pharma Global Development, Inc.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against FLT3 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision